CenterWatch News Online | News and views on the clinical trials industry

Miscellaneous

Prev 10 11 12 13 14 15 16 17 18 19 20 Next 10

etrials Aims for Profitability with Rebuilding Plan

Monday, November 19, 2007 06:45 AM

Morrisville, N.C.-based eClinical company etrials’ third quarter revenue fell and its loss widened amid deep restructuring and organizational changes planned for the next two to three quarters. The company is trying to climb its way to profitability and improve its service delivery issues.

More... »

CWWeekly November 12th Issue

Friday, November 16, 2007 03:16 PM

Top News

More... »

Indian CRO Manipal AcuNova and ECRON GmbH Merge

Friday, November 16, 2007 01:02 PM

Manipal AcuNova, a Bangalore, India-based CRO has acquired ECRON GmbH a of CRO based in Frankfurt, Germany. The new company will have a combined staff of 265 and will be known as ECRON AcuNova. It will provide services for phase I through IV global studies, including project management, data management, biostatistics, medical writing, central lab and BA/BE.

More... »

CenterWatch Monthly November 2007 Issue

Friday, November 16, 2007 12:59 PM

Changes in Asia-Pacific Regulations Position Region for More Growth

More... »

Recent Industry Personnel News

Tuesday, November 13, 2007 06:55 PM

Contract Research

More... »

Drug for Excessive Sleepiness Shows Promise in Phase II Study

Thursday, November 8, 2007 10:23 AM

Vanda Pharmaceuticals reported positive results from a phase II trial of VSF-173, an orally administered stimulant, for the treatment of excessive sleepiness. This randomized, double-blind, placebo-controlled trial enrolled fifty-five subjects who received three doses of VSF-173 administered at 50 mg, 100 mg and 200 mg and placebo administered at 25 mg, 50 mg and 100 mg at the usual bedtime and at four hours after the first dose.

More... »

Michael J. Fox Foundation Gets It and Gets It Done

Wednesday, November 7, 2007 11:09 AM

The Michael J. Fox Foundation (MJFF) for Parkinson's Research gets it. They have figured out just how many bottlenecks there are for getting good research out of academia and to the patient. And Michael J. Fox is willing to put its money where it is needed to move along the drug development process.

More... »

Parexel Reports 26% First Quarter Revenue Increase

Monday, November 5, 2007 04:17 PM

Boston, Mass.-based Parexel International reported service revenue increased 26.1% to $208.1 million for its first quarter of 2008 compared with $165.1 million during the same period of last year. The CRO ended the quarter with operating income of $16.5 million and margins of 7.9%. That compares with $11.3 million for the same period last year and a 6.9% margin. Net income for the quarter was $13.9 million compared with net income of $7 million.

More... »